| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mitral Valve Insufficiency | 8 | 2023 | 99 | 3.330 |
Why?
|
| Heart Failure | 22 | 2023 | 943 | 3.120 |
Why?
|
| Stroke Volume | 13 | 2020 | 338 | 1.490 |
Why?
|
| Mitral Valve | 6 | 2023 | 130 | 1.480 |
Why?
|
| Hypertrophy, Left Ventricular | 11 | 2012 | 124 | 1.290 |
Why?
|
| Ventricular Function, Left | 9 | 2016 | 275 | 1.280 |
Why?
|
| Heart Ventricles | 12 | 2009 | 267 | 0.840 |
Why?
|
| Echocardiography, Doppler | 9 | 2020 | 133 | 0.730 |
Why?
|
| Ventricular Remodeling | 6 | 2023 | 90 | 0.700 |
Why?
|
| Adrenergic beta-Antagonists | 5 | 2007 | 152 | 0.670 |
Why?
|
| Adenosine | 4 | 2004 | 78 | 0.650 |
Why?
|
| Ventricular Dysfunction, Left | 5 | 2017 | 168 | 0.600 |
Why?
|
| Hemodynamics | 4 | 2016 | 253 | 0.600 |
Why?
|
| Myocardial Contraction | 10 | 2012 | 89 | 0.590 |
Why?
|
| Norepinephrine | 3 | 2004 | 107 | 0.560 |
Why?
|
| Blood Pressure | 8 | 2014 | 526 | 0.560 |
Why?
|
| Double Outlet Right Ventricle | 1 | 2016 | 4 | 0.510 |
Why?
|
| Hypertension | 4 | 2012 | 613 | 0.490 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2016 | 14 | 0.480 |
Why?
|
| Models, Cardiovascular | 1 | 2016 | 79 | 0.470 |
Why?
|
| Hemofiltration | 1 | 2014 | 17 | 0.440 |
Why?
|
| Renal Insufficiency | 1 | 2014 | 68 | 0.430 |
Why?
|
| Echocardiography | 11 | 2017 | 512 | 0.410 |
Why?
|
| Renal Dialysis | 1 | 2014 | 195 | 0.400 |
Why?
|
| Lectins, C-Type | 1 | 2013 | 91 | 0.390 |
Why?
|
| Antigens, Neoplasm | 1 | 2013 | 136 | 0.380 |
Why?
|
| Myocardium | 7 | 2004 | 298 | 0.380 |
Why?
|
| Outpatients | 1 | 2013 | 142 | 0.370 |
Why?
|
| Diastole | 7 | 2017 | 91 | 0.370 |
Why?
|
| Male | 38 | 2016 | 31112 | 0.360 |
Why?
|
| Systole | 9 | 2012 | 110 | 0.360 |
Why?
|
| Humans | 44 | 2023 | 65606 | 0.350 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 3 | 2007 | 143 | 0.340 |
Why?
|
| Severity of Illness Index | 5 | 2020 | 1578 | 0.330 |
Why?
|
| Aged | 25 | 2016 | 14966 | 0.330 |
Why?
|
| Rats, Sprague-Dawley | 8 | 2012 | 628 | 0.330 |
Why?
|
| Heart | 4 | 2000 | 295 | 0.330 |
Why?
|
| Decision Making | 1 | 2014 | 420 | 0.320 |
Why?
|
| Biomarkers, Tumor | 1 | 2013 | 524 | 0.310 |
Why?
|
| Natriuretic Peptide, Brain | 3 | 2004 | 58 | 0.300 |
Why?
|
| Mitral Valve Annuloplasty | 2 | 2020 | 19 | 0.300 |
Why?
|
| Female | 31 | 2016 | 34166 | 0.290 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2016 | 722 | 0.290 |
Why?
|
| Rats | 9 | 2012 | 2013 | 0.290 |
Why?
|
| Massachusetts | 11 | 2016 | 2148 | 0.280 |
Why?
|
| Magnetic Resonance Angiography | 3 | 2018 | 187 | 0.280 |
Why?
|
| Coronary Disease | 2 | 2003 | 248 | 0.270 |
Why?
|
| Chronic Disease | 3 | 2017 | 769 | 0.260 |
Why?
|
| Prognosis | 6 | 2014 | 1794 | 0.260 |
Why?
|
| Receptors, Purinergic P1 | 2 | 2004 | 12 | 0.260 |
Why?
|
| Survival Analysis | 2 | 2020 | 591 | 0.250 |
Why?
|
| Pacemaker, Artificial | 2 | 2013 | 51 | 0.240 |
Why?
|
| Ventricular Pressure | 4 | 2007 | 31 | 0.230 |
Why?
|
| Angina, Unstable | 1 | 2005 | 58 | 0.230 |
Why?
|
| Middle Aged | 21 | 2016 | 18299 | 0.230 |
Why?
|
| Cardiomyopathies | 2 | 2009 | 133 | 0.220 |
Why?
|
| Aortic Valve | 3 | 2002 | 192 | 0.220 |
Why?
|
| Presynaptic Terminals | 1 | 2004 | 38 | 0.220 |
Why?
|
| Propanolamines | 1 | 2004 | 10 | 0.210 |
Why?
|
| Carbazoles | 1 | 2004 | 14 | 0.210 |
Why?
|
| Metoprolol | 1 | 2004 | 17 | 0.210 |
Why?
|
| Tetrazoles | 1 | 2004 | 22 | 0.210 |
Why?
|
| Shock, Cardiogenic | 1 | 2005 | 107 | 0.210 |
Why?
|
| Cardiomegaly | 2 | 2001 | 37 | 0.210 |
Why?
|
| Life Style | 1 | 2006 | 320 | 0.210 |
Why?
|
| Benzimidazoles | 1 | 2004 | 57 | 0.200 |
Why?
|
| Cardiac Resynchronization Therapy | 1 | 2023 | 20 | 0.200 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2018 | 799 | 0.190 |
Why?
|
| Myocardial Infarction | 3 | 2005 | 924 | 0.190 |
Why?
|
| Antihypertensive Agents | 1 | 2004 | 179 | 0.190 |
Why?
|
| Dexfenfluramine | 1 | 2002 | 5 | 0.180 |
Why?
|
| Serotonin Receptor Agonists | 1 | 2002 | 13 | 0.180 |
Why?
|
| Radiation Pneumonitis | 1 | 2001 | 2 | 0.180 |
Why?
|
| Adrenergic Antagonists | 1 | 2001 | 3 | 0.170 |
Why?
|
| Cardiomyopathy, Dilated | 2 | 2018 | 39 | 0.170 |
Why?
|
| Hodgkin Disease | 1 | 2001 | 54 | 0.170 |
Why?
|
| Receptors, Adrenergic | 1 | 2000 | 8 | 0.170 |
Why?
|
| Heart Valve Diseases | 1 | 2001 | 95 | 0.160 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2000 | 28 | 0.160 |
Why?
|
| Heart Failure, Diastolic | 2 | 2010 | 9 | 0.160 |
Why?
|
| Disease Progression | 4 | 2012 | 1215 | 0.150 |
Why?
|
| Treatment Outcome | 4 | 2020 | 5829 | 0.150 |
Why?
|
| Dipyridamole | 1 | 1998 | 17 | 0.150 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 1998 | 20 | 0.150 |
Why?
|
| Follow-Up Studies | 5 | 2013 | 2517 | 0.140 |
Why?
|
| Comorbidity | 5 | 2016 | 1123 | 0.140 |
Why?
|
| Protein Kinase C | 1 | 1998 | 103 | 0.140 |
Why?
|
| Observational Studies as Topic | 1 | 2018 | 66 | 0.130 |
Why?
|
| Coronary Vessels | 2 | 1999 | 124 | 0.130 |
Why?
|
| Coronary Artery Bypass | 2 | 2018 | 298 | 0.130 |
Why?
|
| Recurrence | 2 | 2018 | 660 | 0.130 |
Why?
|
| Aged, 80 and over | 9 | 2007 | 5622 | 0.130 |
Why?
|
| In Vitro Techniques | 3 | 2004 | 495 | 0.130 |
Why?
|
| Survival Rate | 3 | 2016 | 863 | 0.120 |
Why?
|
| Atrial Function, Left | 1 | 2016 | 32 | 0.120 |
Why?
|
| Mitoxantrone | 1 | 2016 | 16 | 0.120 |
Why?
|
| Cardiac Catheterization | 2 | 2018 | 305 | 0.120 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2016 | 27 | 0.120 |
Why?
|
| Diuretics | 2 | 2007 | 59 | 0.120 |
Why?
|
| Health Services Administration | 1 | 2015 | 4 | 0.120 |
Why?
|
| Heart Function Tests | 1 | 1995 | 16 | 0.120 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2018 | 187 | 0.110 |
Why?
|
| Animals | 10 | 2012 | 21512 | 0.110 |
Why?
|
| Health Services | 1 | 2015 | 82 | 0.110 |
Why?
|
| Cause of Death | 2 | 2013 | 223 | 0.110 |
Why?
|
| Thoracic Surgery | 1 | 2015 | 79 | 0.110 |
Why?
|
| Uncertainty | 1 | 2014 | 40 | 0.110 |
Why?
|
| Chi-Square Distribution | 3 | 2010 | 416 | 0.110 |
Why?
|
| Computer Simulation | 1 | 2016 | 487 | 0.100 |
Why?
|
| Pancreatitis-Associated Proteins | 1 | 2013 | 4 | 0.100 |
Why?
|
| Cardiology | 1 | 2015 | 170 | 0.100 |
Why?
|
| Academic Medical Centers | 1 | 2015 | 315 | 0.100 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2016 | 193 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 739 | 0.100 |
Why?
|
| Obesity | 1 | 2002 | 1266 | 0.100 |
Why?
|
| Myocardial Ischemia | 1 | 1994 | 117 | 0.100 |
Why?
|
| Biomarkers | 2 | 2013 | 1470 | 0.100 |
Why?
|
| Heart Failure, Systolic | 2 | 2010 | 16 | 0.100 |
Why?
|
| Purinergic P1 Receptor Agonists | 2 | 2004 | 6 | 0.100 |
Why?
|
| Hepatic Veins | 1 | 2013 | 13 | 0.100 |
Why?
|
| Tachycardia, Atrioventricular Nodal Reentry | 1 | 2013 | 6 | 0.100 |
Why?
|
| ROC Curve | 1 | 2013 | 294 | 0.100 |
Why?
|
| Ventricular Function | 2 | 2007 | 22 | 0.100 |
Why?
|
| Hospitalization | 3 | 2010 | 1393 | 0.090 |
Why?
|
| Diagnostic Imaging | 1 | 1995 | 271 | 0.090 |
Why?
|
| Patient Participation | 1 | 2014 | 231 | 0.090 |
Why?
|
| Pulmonary Artery | 1 | 2013 | 99 | 0.090 |
Why?
|
| Prevalence | 4 | 2010 | 1442 | 0.090 |
Why?
|
| Sensitivity and Specificity | 4 | 2016 | 1175 | 0.090 |
Why?
|
| Stress, Mechanical | 2 | 2009 | 111 | 0.090 |
Why?
|
| Perfusion | 3 | 2001 | 73 | 0.090 |
Why?
|
| Retrospective Studies | 6 | 2009 | 6904 | 0.090 |
Why?
|
| Quality of Health Care | 1 | 2015 | 531 | 0.090 |
Why?
|
| Defibrillators, Implantable | 1 | 2014 | 273 | 0.080 |
Why?
|
| Peripheral Arterial Disease | 1 | 2013 | 163 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 1116 | 0.080 |
Why?
|
| Ultrasonography | 3 | 2009 | 494 | 0.080 |
Why?
|
| Acute Disease | 2 | 2010 | 681 | 0.080 |
Why?
|
| Hospital Mortality | 3 | 2005 | 879 | 0.080 |
Why?
|
| Organ Size | 2 | 2001 | 173 | 0.080 |
Why?
|
| Pericardium | 2 | 2000 | 35 | 0.080 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2009 | 50 | 0.070 |
Why?
|
| Age Factors | 2 | 2007 | 1595 | 0.070 |
Why?
|
| Body Weight | 2 | 2001 | 380 | 0.070 |
Why?
|
| Heart Valve Prosthesis | 2 | 2002 | 117 | 0.070 |
Why?
|
| Coronary Circulation | 2 | 2001 | 55 | 0.070 |
Why?
|
| Inpatients | 1 | 2010 | 311 | 0.070 |
Why?
|
| Logistic Models | 2 | 2010 | 1282 | 0.070 |
Why?
|
| Receptor, Adenosine A1 | 1 | 2007 | 10 | 0.060 |
Why?
|
| Risk Factors | 4 | 2016 | 5439 | 0.060 |
Why?
|
| Reference Values | 2 | 2007 | 331 | 0.060 |
Why?
|
| Disease Models, Animal | 3 | 2007 | 2276 | 0.060 |
Why?
|
| Heart Rate | 3 | 2007 | 331 | 0.060 |
Why?
|
| Prospective Studies | 1 | 2013 | 3366 | 0.060 |
Why?
|
| Electrocardiography | 2 | 2003 | 558 | 0.060 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2007 | 186 | 0.060 |
Why?
|
| Population Surveillance | 1 | 2007 | 210 | 0.060 |
Why?
|
| Aging | 2 | 2003 | 767 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2007 | 612 | 0.060 |
Why?
|
| Age Distribution | 1 | 2006 | 260 | 0.060 |
Why?
|
| Necrosis | 2 | 2003 | 145 | 0.060 |
Why?
|
| Diagnosis, Differential | 2 | 2009 | 999 | 0.050 |
Why?
|
| Urban Population | 1 | 2005 | 200 | 0.050 |
Why?
|
| Coronary Angiography | 3 | 2009 | 211 | 0.050 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2004 | 121 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2007 | 1025 | 0.050 |
Why?
|
| Electric Countershock | 1 | 2004 | 105 | 0.050 |
Why?
|
| Incidence | 4 | 2016 | 1411 | 0.050 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2003 | 9 | 0.050 |
Why?
|
| Creatine Kinase | 1 | 2003 | 42 | 0.050 |
Why?
|
| Rhabdomyolysis | 1 | 2003 | 23 | 0.050 |
Why?
|
| Viridans Streptococci | 1 | 2002 | 5 | 0.050 |
Why?
|
| Troponin I | 1 | 2003 | 36 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2004 | 881 | 0.050 |
Why?
|
| Syndrome | 1 | 2003 | 182 | 0.050 |
Why?
|
| Isoenzymes | 1 | 2003 | 142 | 0.050 |
Why?
|
| Patient Education as Topic | 1 | 2006 | 484 | 0.050 |
Why?
|
| Streptococcal Infections | 1 | 2002 | 80 | 0.050 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2002 | 43 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2005 | 466 | 0.050 |
Why?
|
| Abscess | 1 | 2002 | 80 | 0.050 |
Why?
|
| Purinergic P1 Receptor Antagonists | 1 | 2001 | 4 | 0.040 |
Why?
|
| Inosine | 1 | 2001 | 5 | 0.040 |
Why?
|
| Isoproterenol | 1 | 2001 | 37 | 0.040 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2001 | 34 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2001 | 208 | 0.040 |
Why?
|
| Caffeine | 1 | 2001 | 47 | 0.040 |
Why?
|
| Myocardial Reperfusion | 1 | 2000 | 24 | 0.040 |
Why?
|
| Ischemic Preconditioning, Myocardial | 1 | 2000 | 23 | 0.040 |
Why?
|
| Endocardium | 1 | 1999 | 14 | 0.040 |
Why?
|
| Survival | 1 | 1998 | 11 | 0.040 |
Why?
|
| Registries | 1 | 2002 | 905 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 1998 | 389 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 1702 | 0.030 |
Why?
|
| Calcium | 1 | 2001 | 587 | 0.030 |
Why?
|
| Case-Control Studies | 3 | 2009 | 1158 | 0.030 |
Why?
|
| Heart Diseases | 1 | 1999 | 226 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2001 | 2209 | 0.030 |
Why?
|
| United States | 3 | 2009 | 8138 | 0.030 |
Why?
|
| Syncope | 1 | 1996 | 41 | 0.030 |
Why?
|
| Causality | 1 | 2016 | 59 | 0.030 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2015 | 7 | 0.030 |
Why?
|
| Atrial Fibrillation | 1 | 2004 | 872 | 0.030 |
Why?
|
| Bioprosthesis | 1 | 1996 | 42 | 0.030 |
Why?
|
| Time Factors | 3 | 2009 | 3783 | 0.030 |
Why?
|
| Cardiac Output | 1 | 1994 | 28 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 325 | 0.030 |
Why?
|
| Regional Blood Flow | 1 | 1994 | 112 | 0.030 |
Why?
|
| Odds Ratio | 2 | 2010 | 764 | 0.030 |
Why?
|
| Lung | 1 | 1998 | 972 | 0.030 |
Why?
|
| Aorta | 1 | 1994 | 114 | 0.030 |
Why?
|
| Dogs | 1 | 1994 | 340 | 0.020 |
Why?
|
| Equipment Failure Analysis | 1 | 2013 | 79 | 0.020 |
Why?
|
| Device Removal | 1 | 2013 | 67 | 0.020 |
Why?
|
| Adult | 5 | 2009 | 17448 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 682 | 0.020 |
Why?
|
| Cardiotonic Agents | 1 | 2009 | 54 | 0.020 |
Why?
|
| Biomechanical Phenomena | 1 | 2009 | 283 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1995 | 1689 | 0.020 |
Why?
|
| Stress, Physiological | 1 | 2009 | 209 | 0.020 |
Why?
|
| Midazolam | 1 | 2004 | 12 | 0.010 |
Why?
|
| Blood Pressure Determination | 1 | 2004 | 40 | 0.010 |
Why?
|
| Anesthetics, Intravenous | 1 | 2004 | 26 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 2009 | 484 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2004 | 158 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2004 | 215 | 0.010 |
Why?
|
| Fentanyl | 1 | 2004 | 73 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2010 | 2099 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2009 | 2640 | 0.010 |
Why?
|
| Demography | 1 | 2002 | 180 | 0.010 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2002 | 174 | 0.010 |
Why?
|
| Drug Utilization | 1 | 2002 | 208 | 0.010 |
Why?
|
| Survivors | 1 | 2002 | 184 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2007 | 1579 | 0.010 |
Why?
|
| Rats, Inbred F344 | 1 | 2000 | 56 | 0.010 |
Why?
|
| Disease Management | 1 | 2002 | 237 | 0.010 |
Why?
|
| Hospitals | 1 | 2002 | 391 | 0.010 |
Why?
|
| Myocardial Revascularization | 1 | 1999 | 78 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1999 | 106 | 0.010 |
Why?
|
| Observer Variation | 1 | 1999 | 215 | 0.010 |
Why?
|
| Tilt-Table Test | 1 | 1996 | 11 | 0.010 |
Why?
|
| Mechanoreceptors | 1 | 1996 | 13 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2003 | 2703 | 0.010 |
Why?
|
| Aortic Valve Stenosis | 1 | 1996 | 194 | 0.010 |
Why?
|